Medivir: Medivir's CEO increases his shareholding in the company
Business Wire - Tue May 12, 6:11AM CDT
Regulatory News:
Medivir posts profit of SEK66.7m in Q1 2015
M2 - Wed May 06, 7:04AM CDT
Medivir AB (STO: MVIR) on Tuesday reported profit after tax of SEK66.7m, or diluted EPS of SEK2.27, for the first quarter of 2015, from January 2015 to March 2015.
MVIR: ()
Medivir's Board of Directors Has Resolved to Repurchase Own Shares
Business Wire - Wed May 06, 1:58AM CDT
Regulatory News:
Medivir AB - Interim Report January - March 2015
Business Wire - Tue May 05, 3:21AM CDT
Regulatory News:
MVIR: ()
Medivir: Positive preclinical antiviral and safety profile of MIV-802 supports continued development
Business Wire - Thu Apr 23, 7:11AM CDT
Regulatory News:
Medivir: Data from OPTIMIST trials show SVR12 rates of 97 percent in HCV patients without cirrhosis and 84 percent in HCV patients with cirrhosis
Business Wire - Thu Apr 23, 3:39AM CDT
Regulatory News:
Medivir earns €13.8M Olysio royalty in Q1
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:06AM CDT
Medivir: OLYSIO(R) sales during the first quarter 2015
Business Wire - Tue Apr 14, 7:08AM CDT
Regulatory News:
Medivir and Cancer Research Technology Collaborate to Develop New Class of Cancer Drugs
Business Wire - Mon Apr 13, 1:36AM CDT
Regulatory News:
Medivir: Annual Report 2014
Business Wire - Tue Apr 07, 1:50AM CDT
Regulatory News:
Notice of Annual General Meeting of Medivir AB (publ)
Business Wire - Wed Apr 01, 1:49AM CDT
Regulatory News:
Medivir: New Data on Simeprevir Presented at the Conference of the Asian Pacific Association for the Study of the Liver
Business Wire - Mon Mar 16, 2:41AM CDT
Regulatory News:
Medivir Capital Markets Meeting on 26 March 2015
Business Wire - Thu Mar 12, 2:43AM CDT
Regulatory News:
Medivir: New Members of Medivir's Management Group
Business Wire - Mon Mar 02, 7:35AM CST
Regulatory News:
MVIR: ()
Medivir announces proposal for new board of directors by nomination committee ahead of AGM 2015
M2 - Thu Feb 19, 5:47AM CST
Medivir AB (OMX: MVIR), a research based pharmaceutical company with a research focus on infectious diseases and oncology, announced on Wednesday that the company's nomination committee's proposal for a new board of directors will be submitted to the 2015 Annual General Meeting.
MVIR: ()
Medivir's Nomination Committee proposes new Board of Directors ahead of 2015 AGM
Business Wire - Wed Feb 18, 1:41AM CST
Regulatory News:
MVIR: ()
Final Terms for Medivir's Voluntary Redemption Programme
Business Wire - Fri Jan 30, 2:03AM CST
Regulatory News:
Medivir announces acquisition of SEK2.1m worth of shares by CEO
M2 - Wed Jan 28, 5:40AM CST
Research-based pharmaceutical company Medivir AB (STO:MVIRB) announcedon Wednesday that the company's CEO, Niklas Prager, has bought 23,600 class B shares in Medivir at an acquisition price of approximately SEK2.1m.